[1] |
American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee, Draznin B, et al. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S17-S38.
doi: 10.2337/dc22-S002
|
[2] |
Wherrett DK, Chiang JL, Delamater AM, et al. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report[J]. Diabetes Care, 2015, 38(10): 1975-1985.
doi: 10.2337/dc15-1429
pmid: 26404927
|
[3] |
Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: A position statement by the American diabetes association[J]. Diabetes Care, 2018, 41(9): 2026-2044.
doi: 10.2337/dci18-0023
pmid: 30093549
|
[4] |
Chamberlain JJ, Kalyani RR, Leal S, et al. Treatment of type 1 diabetes: Synopsis of the 2017 American diabetes association standards of medical care in diabetes[J]. Ann Intern Med, 2017, 167(7): 493-498.
doi: 10.7326/M17-1259
pmid: 28892816
|
[5] |
Gamble A, Pepper AR, Bruni A, et al. The journey of islet cell transplantation and future development[J]. Islets, 2018, 10(2): 80-94.
doi: 10.1080/19382014.2018.1428511
|
[6] |
Chetboun M, Jannin A, Kerr-Conte J, et al. 1921-2021: From insulin discovery to islet transplantation in type 1 diabetes[J]. Ann Endocrinol (Paris), 2021, 82(2): 74-77.
doi: 10.1016/j.ando.2021.03.006
|
[7] |
Brooks AM, Oram R, Home P, et al. Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation[J]. Diabetes Care, 2015, 38(1): 105-112.
doi: 10.2337/dc14-1656
|
[8] |
Vantyghem MC, Raverdy V, Balavoine AS, et al. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3)[J]. J Clin Endocrinol Metab, 2012, 97(11): E2078- E2083.
|
[9] |
Shapiro AM, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation[J]. Nat Rev Endocrinol, 2017, 13(5): 268-277.
doi: 10.1038/nrendo.2016.178
pmid: 27834384
|
[10] |
Dugbartey GJ. Carbon monoxide in pancreatic islet transplantation: A new therapeutic alternative to patients with severe type 1 diabetes mellitus[J]. Front Pharmacol, 2021, 12: 750816.
doi: 10.3389/fphar.2021.750816
|
[11] |
Marfil-Garza BA, Hefler J, Bermudez De Leon M, et al. Progress in translational regulatory T cell therapies for type 1 diabetes and islet transplantation[J]. Endocr Rev, 2021, 42(2): 198-218.
doi: 10.1210/endrev/bnaa028
pmid: 33247733
|
[12] |
Tootee A, Nikbin B, Ghahary A, et al. Assessment of immune-alternations and their correlations with therapeutic outcomes of transplantation of autologous Mesenchymal and Allogenic fetal stem cells in patients with type 1 diabetes: a study protocol[J]. J Diabetes Metab Disord, 2021, 20(1): 1067-1073.
doi: 10.1007/s40200-020-00716-9
|
[13] |
Lu J, Shen SM, Ling Q, et al. One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study[J]. Stem Cell Res Ther, 2021, 12(1): 340.
doi: 10.1186/s13287-021-02417-3
|
[14] |
Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus[J]. JAMA, 2007, 297(14): 1568-1576.
doi: 10.1001/jama.297.14.1568
pmid: 17426276
|
[15] |
Malmegrim KC, de Azevedo JT, Arruda LC, et al. Immunological balance is associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes[J]. Front Immunol, 2017, 8:167.
doi: 10.3389/fimmu.2017.00167
pmid: 28275376
|
[16] |
Lindahl JP, Hartmann A, Horneland R, et al. Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease[J]. Diabetologia, 2013, 56(6): 1364-1371.
doi: 10.1007/s00125-013-2888-y
pmid: 23549518
|
[17] |
Chudek J, Kolonko A, Ziaja J, et al. Beneficial effect of successful simultaneous pancreas-kidney transplantation on plasma profile of metalloproteinases in type 1 diabetes mellitus patients[J]. J Clin Med, 2021, 10(17): 3800.
doi: 10.3390/jcm10173800
|
[18] |
Cho JA, Chinnapen DJF. Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease[J]. J Microbiol, 2018, 56(3): 183-188.
doi: 10.1007/s12275-018-8037-z
|
[19] |
Mariño E, Richards JL, McLeod KH, et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes[J]. Nat Immunol, 2017, 18(5): 552-562.
doi: 10.1038/ni.3713
|
[20] |
de Groot P, Nikolic T, Pellegrini S, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial[J]. Gut, 2021, 70(1): 92-105.
doi: 10.1136/gutjnl-2020-322630
|